Trial Profile
Phase lV Study to Evaluate the Safety and Effectiveness of Switching Treatment From Lamivudine to Clevudine in the Chronic Hepatitis B Patients With Suboptimal Virologic Response During Lamivudine Treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2015
Price :
$35
*
At a glance
- Drugs Clevudine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bukwang Pharmaceutical
- 25 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2007 New trial record.